Tag: announcement

As of June 20th, 2025, Novonesis has purchased an accumulated 1,660,344 shares with a transaction value of DKK 713,0 million under the share buyback program announced by Novonesis in Company announcement No. 3, 2025 and initiated on March 5, 2025. Under the program, Novonesis will buy back B shares worth up to EUR 100 million (DKK 746 million) in total during the remainder of 2025.

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Verizon Communications Inc. (“Verizon”) (NYSE, Nasdaq: VZ) today announced the final results of its Exchange Offers (as defined below) and its Cash Offers (as defined below).

BOCA RATON, FL, June 23, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first US public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced a landmark partnership with Kraken to list the tokenized stock of its publicly traded equity on the Solana blockchain. As part of the xStocks alliance, Kraken is partnered with Backed and Solana to offer tokenized equities on the Kraken platform.

Back on the USA TODAY’s 10Best ballot and ready to defend its title, Habit’s reigning #1 Double Char is just $1 at participating locations for a limited time

Golar LNG Limited (“Golar”) is pleased to announce that FLNG Gimi has reached the Commercial Operations Date (“COD”) for its 20-year Lease and Operate Agreement for the Greater Tortue Ahmeyim (“GTA”) project offshore Mauritania and Senegal. The COD triggers the start of the 20-year Lease and Operate Agreement that unlocks the equivalent of around $3 billion of Adjusted EBITDA backlog (Golar's share).

Company Announcement No 52/2025  

Two Argentine crews complete the podium: second Erejomovich-Llanos, third Tonconogy-Ruffini

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.

REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.